RYAN C NOKES: Open Payments
NPI 1053773739 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,007 in 101 payments from 13 companies in 2025. Trend: 2023 $833 · 2024 $2,315 · 2025 $3,007
Food & beverage: $3,004Education: $3
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $829 |
| Alkermes, Inc. | 17 | $615 |
| Neurocrine BioSciences, Inc. | 14 | $479 |
| E.R. Squibb & Sons, L.L.C. | 9 | $237 |
| Otsuka America Pharmaceutical, Inc. | 12 | $236 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $173 |
| Vanda Pharmaceuticals Inc. | 5 | $141 |
| Janssen Scientific Affairs, LLC | 1 | $115 |
| Axsome Therapeutics, Inc. | 4 | $85 |
| Sage Therapeutics, LLC | 3 | $47 |
Products named: VRAYLAR, ARISTADA, INGREZZA, COBENFY, CAPLYTA, FANAPT, REXULTI, INVEGA SUSTENNA.
Industry payments across NV — which companies pay providers there.
